Skip to main content
. Author manuscript; available in PMC: 2022 Jan 15.
Published in final edited form as: Cancer. 2020 Oct 20;127(2):300–309. doi: 10.1002/cncr.33184

Table 4.

Linear Regression Model of the Impact of the Presence of Lymphedema on Participants’ HRQL at 18 Months adjusted for Intervention Group, Demographic and Clinical Variables

Variable Level Estimate Standard Error P-Value Overall P-Value
Lymphedema Intervention Group LEAP −0.6161 1.1482 0.5921 0.5921
Education Only (EO) Reference
Immediate reconstructive surgery Yes −1.8887 1.5627 0.2281 0.2281
No Reference
Definitive primary surgery Mastectomy, NOS 1.1734 1.4323 0.4135 0.4135
Partial mastectomy/lumpectomy/excisional biopsy Reference
Race African-American −2.0784 1.6039 0.1964 0.3549
Other 1.4292 2.8702 0.6190
White Reference
ECOG Performance Status 1 & 2 −4.2272 2.3780 0.0768 0.0768
0 Reference
Number of positive lymph nodes 1–3 0.8704 1.5469 0.5742 0.2989
4+ −2.1654 2.1082 0.3055
0 Reference
Lymphedema Yes −2.3175 1.3288 0.0825 0.0825
No Reference
Education At least some college 0.6585 1.3911 0.6364 0.4045
Post College work/degree 2.0368 1.5706 0.1961
HS Grad or less Reference
Chemotherapy Yes −1.1679 1.3790 0.3980 0.3980
No Reference
AND/SND Status Axillary node dissection only −0.4700 1.6435 0.7752 0.9123
Sentinel node biopsy only −0.6072 1.5351 0.6928
Both Axillary node dissection and sentinel node biopsy Reference
Age 1 more year 0.04319 0.05546 0.4369 0.4369
Baseline FACT-B+4 Total Score 0.6572 0.05971 <.0001 <.0001